Super Bowl, Hims

The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the ...
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers' future growth is expected from personalized solutions, with potential to expand the subscriber base by millions.
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...